What causes sjs

Overview

Stevens-Johnson syndrome (SJS) and its more severe form, toxic epidermal necrolysis (TEN), are rare but serious adverse drug reactions that affect the skin and mucous membranes. These conditions are characterized by widespread blistering and peeling of the skin, resembling a severe burn. They can be life-threatening due to the extensive skin damage, fluid loss, and increased risk of infection. While often associated with medications, other factors can also play a role in their development.

What Triggers SJS/TEN?

The vast majority of SJS/TEN cases are attributed to medications. When a person takes a drug that triggers this reaction, their immune system mistakenly attacks healthy skin cells. This immune response leads to inflammation, blistering, and the eventual shedding of the skin. The reaction can occur at any point during treatment, but it is most common within the first two weeks of starting a new medication.

Medications as the Primary Cause

Numerous medications have been implicated in SJS/TEN, but some are more frequently associated than others. These include:

• Anticonvulsants (antiepileptic drugs): Such as lamotrigine, carbamazepine, phenytoin, and phenobarbital.
• Antibiotics: Particularly sulfonamides (like trimethoprim-sulfamethoxazole), penicillins, and cephalosporins.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): Especially oxicams (e.g., piroxicam).
• Allopurinol: A medication used to treat gout.
• Nevirapine: An antiretroviral medication used to treat HIV.

It's crucial to note that any drug can potentially cause SJS/TEN, even those previously tolerated. The risk is generally higher with certain drugs and in individuals with specific genetic makeup.

Infections as a Trigger

While less common than drug reactions, infections are another significant cause of SJS/TEN, especially in children. The most frequently identified infectious trigger is Mycoplasma pneumoniae, a type of bacteria that causes respiratory infections like walking pneumonia. Other infections that have been linked to SJS/TEN include:

• Herpes simplex virus (HSV)
• Varicella-zoster virus (VZV), which causes chickenpox and shingles
• Influenza
• Hepatitis
• Dengue fever

In many cases, especially with viral infections, the SJS/TEN reaction is thought to occur as the body's immune system fights off the infection.

Genetic Predisposition

Emerging research highlights the role of genetic factors in determining an individual's susceptibility to SJS/TEN. Certain gene variations, particularly within the Human Leukocyte Antigen (HLA) system, are strongly associated with an increased risk of developing SJS/TEN when exposed to specific drugs. For example:

• Individuals with the HLA-B*1502 allele are at a significantly higher risk of developing SJS/TEN when taking carbamazepine. This allele is more common in people of Asian descent.
• The HLA-B*5801 allele is associated with an increased risk of SJS/TEN from allopurinol, particularly in Han Chinese and Thai populations.

These genetic markers help explain why some people develop SJS/TEN while others taking the same medication do not.

Other Potential Factors

While medications and infections are the leading causes, other factors may contribute or increase the risk:

• Human Immunodeficiency Virus (HIV) infection: People with HIV have a higher risk of developing SJS/TEN, possibly due to altered immune function and increased use of certain medications.
• Weakened Immune System: Conditions that compromise the immune system, such as chemotherapy or immunosuppressive therapy, might play a role, although this is less clearly defined.
• Systemic Lupus Erythematosus (SLE): Some studies suggest a link, but more research is needed.

Understanding the Mechanism

The exact mechanism by which SJS/TEN develops is complex and not fully understood. However, it is believed to involve a hypersensitivity reaction where the immune system targets specific proteins on the surface of skin and mucous membrane cells. This targeted attack leads to the death of these cells (keratinocytes), resulting in the characteristic blisters and epidermal detachment. The release of inflammatory mediators exacerbates the damage.

Diagnosis and Management

If SJS/TEN is suspected, immediate medical attention is critical. Diagnosis is usually based on the clinical presentation and a thorough review of the patient's medication history. A skin biopsy may be performed to confirm the diagnosis. Management involves discontinuing the suspected causative agent immediately, supportive care (fluid and electrolyte management, wound care, pain control), and often treatment in a specialized burn unit or intensive care unit.

Prevention

Given that medications are the most common cause, prevention strategies focus on careful prescribing and patient awareness. Healthcare providers should:

• Review a patient's medication history thoroughly, including over-the-counter drugs and supplements.
• Be aware of drugs with a higher risk of SJS/TEN.
• Consider genetic testing for individuals with a higher risk profile before prescribing certain medications (e.g., HLA-B*1502 testing before carbamazepine in at-risk populations).
• Educate patients about the signs and symptoms of SJS/TEN and advise them to seek immediate medical help if they develop a rash, blistering, or sores on the mouth, eyes, or genitals after starting a new medication.

While SJS/TEN is a serious condition, prompt recognition and management significantly improve outcomes. Understanding the potential triggers is the first step toward prevention and early intervention.